WO2018059429A1 - 一种非溶剂化晶体及其制备方法与应用 - Google Patents

一种非溶剂化晶体及其制备方法与应用 Download PDF

Info

Publication number
WO2018059429A1
WO2018059429A1 PCT/CN2017/103620 CN2017103620W WO2018059429A1 WO 2018059429 A1 WO2018059429 A1 WO 2018059429A1 CN 2017103620 W CN2017103620 W CN 2017103620W WO 2018059429 A1 WO2018059429 A1 WO 2018059429A1
Authority
WO
WIPO (PCT)
Prior art keywords
unsolvated
crystal
aminophenyl
methoxyquinolin
oxo
Prior art date
Application number
PCT/CN2017/103620
Other languages
English (en)
French (fr)
Inventor
鲁先平
李志斌
Original Assignee
深圳微芯生物科技有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201904447A priority Critical patent/UA123746C2/uk
Priority to AU2017333056A priority patent/AU2017333056B2/en
Priority to RU2019112457A priority patent/RU2019112457A/ru
Priority to CA3038384A priority patent/CA3038384C/en
Priority to BR112019005995A priority patent/BR112019005995A2/pt
Priority to EP17854879.8A priority patent/EP3524594A4/en
Application filed by 深圳微芯生物科技有限责任公司 filed Critical 深圳微芯生物科技有限责任公司
Priority to MX2019003458A priority patent/MX2019003458A/es
Priority to KR1020197012102A priority patent/KR20190053952A/ko
Priority to US16/337,389 priority patent/US10882825B2/en
Priority to JP2019517848A priority patent/JP7339884B2/ja
Publication of WO2018059429A1 publication Critical patent/WO2018059429A1/zh
Priority to ZA2019/02628A priority patent/ZA201902628B/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of medicinal chemistry, in particular to an unsolvated crystal of N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide and a preparation method thereof application.
  • N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide is a protein kinase and histone deacetylase dual target inhibitor, The chemical structure is as shown in the structural formula (I).
  • the pharmacological activity of the compound of formula (I) is described in Chinese patent application CN200910223861.5, which has protein kinase inhibitory activity and histone deacetylase inhibitory activity, and can be used for treatment and abnormal protein kinase activity and histone deacetylation.
  • Diseases associated with abnormal enzyme activities including inflammation, autoimmune diseases, cancer, nervous system diseases, and neurodegenerative diseases, Cardiovascular diseases, metabolic diseases, allergies, asthma, and hormone-related diseases, especially for blood cancer and solid tumors.
  • the solid of the compound of formula (I) prepared by this process inevitably contains N,N-dimethylformamide (DMF), which has been confirmed by its proton nuclear magnetic resonance spectrum ( 1 H NMR).
  • the resulting solid was a solvated crystal of N,N-dimethylformamide (DMF) containing 1.4% DMF.
  • ICH International Conference of Harmonizition
  • ICH International Conference of Harmonizition
  • toluene ethyl acetate, butyl acetate, dimethyl sulfoxide (DMSO), ethanol, and methyl isobutyl ketone are 0.088%, 0.006%, 0.3%, 0.072%, 0.089%, 0.5%, 0.5, respectively. %, 0.5%, 0.5% and 0.5%.
  • the compound of the formula (I) obtained by the method of Example 31 of the Chinese patent application CN200910223861.5 has a residual amount of DMF far exceeding the limit prescribed by ICH.
  • ICH the limit prescribed by ICH.
  • the present invention provides three unsolvated crystals of the compound of formula (I).
  • the non-solvated crystal A of the compound of formula (I) has an X-ray powder diffraction pattern at reflection angles 2 ⁇ of about 4.42°, 6.88°, 8.78°, 9.26°, 12.74°, 13.82°, 15.78°, 18.58°, 20.86°.
  • characteristic absorption peaks at 1253, 1224, 1161, 1088 and 1024 cm -1 There are characteristic absorption peaks at 1253, 1224, 1161, 1088 and 1024 cm -1 ; the differential scanning calorimetry curve has an endothermic peak at about 177.5 ° C, 213.1 ° C and 220.8 ° C; its proton nuclear magnetic resonance spectrum indicates that the crystal does not contain Machine solvent, fully in line with ICH's requirements for solvent residue limits.
  • the non-solvated crystal B of the compound of formula (I) has an X-ray powder diffraction pattern at reflection angles 2 ⁇ of about 4.88°, 9.68°, 12.74°, 14.52°, 17.72°, 19.82°, 21.86°, 24.30°, 25.26°.
  • Characteristic peak its infrared spectrum has characteristics at about 3423, 3352, 3238, 3030, 1624, 1597, 1531, 1502, 1452, 1423, 1388, 1365, 1308, 1255, 1226, 1159, 1086, 1022 cm -1 Absorption peak; its differential scanning calorimetry curve has an endothermic peak at about 178.6 ° C; its proton nuclear magnetic resonance spectrum indicates that the crystal does not contain organic solvents, which fully meets the ICH requirements for solvent residue limits.
  • the non-solvated crystal C of the compound of formula (I) has an X-ray powder diffraction pattern at reflection angles 2 ⁇ of about 4.84°, 9.68°, 12.92°, 14.60°, 16.46°, 17.20°, 17.44°, 17.88°, 19.20°.
  • the infrared spectrum is about 3452, 3369, 3217, 3016, 2962, 1793, 1728, 1626, 1595, 1574, 1531, 1502, 1448 , 1429, 1388, 1311, 1252, 1224, 1159, 1020 cm -1 have characteristic absorption peaks;
  • the differential scanning calorimetry curve has an endothermic peak at about 196.3 ° C and 221.0 ° C; its proton nuclear magnetic resonance spectrum indicates the crystal It does not contain organic solvents and is fully compliant with the ICH solvent residue limits.
  • an unsolvated crystal of N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide is provided.
  • the unsolvated crystal comprises unsolvated crystal A of N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide , B and C.
  • the unsolvated crystal A is characterized by its X-ray powder
  • the final diffraction pattern has characteristic peaks at reflection angles (2 ⁇ ) of 6.88°, 9.26°, 12.74°, 13.82°, 18.58°, 20.86°, and 25.72°; preferably, its X-ray powder diffraction pattern is at the reflection angle (2 ⁇ ) Characteristic peaks at 4.42°, 6.88°, 8.78°, 9.26°, 12.74°, 13.82°, 18.58°, 20.86°, and 25.72°; more preferably, the X-ray powder diffraction pattern is at a reflection angle (2 ⁇ ) of 4.42° Characteristic peaks at 6.88°, 8.78°, 9.26°, 12.74°, 13.82°, 15.78°, 18.58°, 20.86°, 22.56°, 25.72°, 27.08° and 28.72°; most preferably, their X-ray powder
  • the diffraction pattern is shown in Figure 2.
  • the infrared spectrum of the unsolvated crystal A is 3452, 3404, 3357, 3230, 3064, 1622, 1576, 1525, 1506, 1452, 1423, 1388, 1363, 1311, 1253, 1224, 1161.
  • the unsolvated crystal B is characterized by an X-ray powder diffraction pattern at reflection angles (2 ⁇ ) of 4.88°, 9.68°, 12.74°, 14.52°, 17.72°, 24.30°, 25.26°. Characteristic peaks; preferably, the X-ray powder diffraction pattern has characteristics at reflection angles (2 ⁇ ) of 4.88°, 9.68°, 12.74°, 14.52°, 17.72°, 19.82°, 21.86°, 24.30°, 25.26°. More preferably, its X-ray powder diffraction pattern is shown in Figure 5.
  • the infrared spectrum of the unsolvated crystal B is 3423, 3352, 3238, 3030, 1624, 1597, 1531, 1502, 1452, 1423, 1388, 1365, 1308, 1255, 1226, 1159, 1086.
  • There is a characteristic absorption peak at 1022 cm -1 preferably as shown in Figure 6; its differential scanning calorimetry curve has an endothermic peak at 178.6 ° C, preferably as shown in Figure 7.
  • the unsolvated crystal C is characterized by an X-ray powder diffraction pattern at reflection angles (2 ⁇ ) of 4.84°, 9.68°, 12.92°, 14.60°, 16.46°, 17.44°, 22.00°. , having a characteristic peak at 25.28°; preferably, the X-ray powder diffraction pattern is at a reflection angle (2 ⁇ ) of 4.84°, 9.68°, 12.92°, 14.60°, 16.46°, 17.44°, 17.88°, 22.00°, 25.28°.
  • X-ray powder diffraction pattern having a characteristic peak at 27.66°; more preferably, its X-ray powder diffraction pattern is at a reflection angle (2 ⁇ ) 4.84 Characteristic peaks at °, 9.68, 12.92, 14.60, 16.46, 17.20, 17.44, 17.88, 19.20, 20.54, 21.06, 22.00, 25.28, 27.66; most preferably, The X-ray powder diffraction pattern is shown in Fig. 8.
  • the infrared spectrum of the unsolvated crystal C is 3452, 3369, 3217, 3016, 2962, 1793, 1728, 1626, 1595, 1574, 1531, 1502, 1448, 1429, 1388, 1311, 1252
  • the differential scanning calorimetry curve has an endothermic peak at 196.3 ° C and 221.0 ° C, preferably as shown in FIG.
  • the invention also provides a process for the preparation of three unsolvated crystals of a compound of formula (I).
  • Process for the preparation of unsolvated crystalline A of a compound of formula (I) comprises the steps of: N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1- Naphthylcarboxamide was added to methanol, dissolved by heating at 65 ° C, and cooled at 0 ° C.
  • the method for preparing unsolvated crystal A comprises the steps of: N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalene
  • the formamide was added to methanol, dissolved by heating at 65 ° C, and cooled at 0 ° C.
  • the solid was collected by filtration and dried under vacuum at 80 ° C for 12 hours.
  • the method for preparing unsolvated crystal B comprises the steps of: N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalene
  • the formamide was added to acetonitrile, dissolved by heating at 80 ° C, cooled and precipitated at 0 ° C, collected by filtration, and dried under vacuum at 80 ° C for 12 hours.
  • Process for the preparation of unsolvated crystalline C of a compound of formula (I) which comprises the steps of: N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1- Naphthocarboxamide was added to dimethyl sulfoxide, dissolved by stirring at room temperature, and the resulting solution was added dropwise to water with stirring, and the solid was collected by filtration.
  • the method for preparing unsolvated crystal C comprises the steps of: N-(2-amino) Phenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide was added to dimethyl sulfoxide and dissolved by stirring at room temperature. The resulting solution was added dropwise to the mixture with stirring and collected by filtration. The solid was washed with water and dried under vacuum at 80 ° C for 24 hours.
  • a pharmaceutical composition comprising N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide Unsolvated crystals.
  • the invention provides a pharmaceutical composition for treating a disease associated with abnormal protein kinase activity or abnormality of histone deacetylase activity, comprising N-(2-aminophenyl)-6 Non-solvated crystals of (7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide, and optionally pharmaceutically acceptable excipients and/or carriers.
  • compositions of the invention may contain any suitable pharmaceutically acceptable excipients and/or carriers.
  • the pharmaceutical compositions of the present invention can be prepared by conventional techniques, such as those described in Remington: The Science and Practice of Pharmacy, 19th edition, 1995, which is incorporated herein by reference.
  • the composition may be presented in conventional forms such as tablets, capsules, powders, granules, suspensions, syrups, solutions, solutions, ointments, and the like.
  • the formulation usually contains from 0.5% to 70% by weight of the compound of the formula (I) and from 30% to 99.5% by weight of the pharmaceutically acceptable excipient, preferably from 1% to 65% by weight, from 3% to 60% by weight, from 5% to 55%. Wt, 10% to 50% by weight, 20% to 40% by weight, 25% to 38% by weight, 30% to 35% by weight or 32% to 34% by weight of the compound of the formula (I).
  • a typical composition comprises a compound of the invention and an excipient or carrier.
  • the active compound is usually mixed with the carrier, or diluted by the carrier, or enclosed in a carrier which may be in the form of an ampule, capsule, sachet, paper or other container.
  • the carrier can be a solid, semi-solid or liquid material that serves as a carrier, excipient or medium for the active compound.
  • the active compound can be adsorbed onto a particulate solid carrier (e.g., contained in a sachet).
  • suitable carriers are water, saline solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, rings.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or a mixture thereof with a wax.
  • the present invention provides an unsolvated crystal of N-(2-aminophenyl)-6-(7-methoxyquinolin-4-oxo)-1-naphthalenecarboxamide in preparation.
  • a disease associated with abnormal protein kinase activity or abnormal histone deacetylase activity is selected from the group consisting of inflammation, autoimmune diseases, cancer, nervous system diseases and neurodegenerative diseases, cardiovascular diseases, metabolic diseases, allergies. , asthma and hormone-related diseases, especially blood cancer and solid tumors.
  • the unsolvated crystals A, B and C of the compound of formula (I) were placed under high temperature (60 ° C), high humidity (90% 5%) and intense light irradiation (4500 Lx 500 Lx) for 10 days.
  • the original crystal form remained unchanged, and the content of each crystal did not change significantly, indicating that all three crystals are suitable for pharmaceutical manufacturing and long-term storage.
  • Figure 1 is an X-ray powder diffraction pattern of a solid prepared in accordance with Example 31 of Chinese Patent Application No. CN200910223861.5.
  • Example 2 is an X-ray powder diffraction pattern of unsolvated crystal A of a compound of formula (I) prepared in accordance with Example 1 of the present invention.
  • Figure 5 is an unsolvated crystal B of a compound of formula (I) prepared according to Example 2 of the present invention. X-ray powder diffraction pattern.
  • Figure 6 is an infrared spectrum of unsolvated crystal B of a compound of formula (I) prepared in accordance with Example 2 of the present invention.
  • Figure 7 is a differential scanning calorimetry analysis of unsolvated crystal B of a compound of formula (I) prepared in accordance with Example 2 of the present invention.
  • Figure 8 is an X-ray powder diffraction pattern of unsolvated crystal C of a compound of formula (I) prepared in accordance with Example 3 of the present invention.
  • Figure 9 is an infrared spectrum of unsolvated crystal C of a compound of formula (I) prepared in accordance with Example 3 of the present invention.
  • Figure 10 is a differential scanning calorimetry analysis of unsolvated crystal C of a compound of formula (I) prepared in accordance with Example 3 of the present invention.
  • Infrared spectroscopy test conditions Instrument: RFX-65A (Analect, USA); KBr tableting method.
  • Proton nuclear magnetic resonance test conditions instrument: AV-400 (BRUKER, Germany); solvent: DMSO-d 6 .
  • Stability test conditions High temperature (60 ° C), high humidity (90%) and strong light (4500 Lx) tests were carried out according to the Chinese Pharmacopoeia 2010 edition two appendix XIX C.
  • HPLC test conditions instrument: Dai An UltiMate 3000; column: Shim-pack VP-ODS 5 ⁇ m 250L ⁇ 4.6; detector: VWD-3100, detection wavelength: 256 nm; mobile phase: methanol-water-glacial acetic acid (30:70: 0.4); flow rate; 1.0 mL/min, column temperature: 30 °C.
  • the reflection angles 2 ⁇ are about 4.42°, 6.88°, 8.78°, 9.26°, 12.74°, 13.82°, 15.78°, 18.58°, 20.86°, 22.56°, 25.72°. Characteristic peaks at 27.08° and 28.72°; the infrared spectrum is shown in FIG. 3, at about 3452, 3404, 3357, 3230, 3064, 1622, 1576, 1525, 1506, 1452, 1423, 1388, 1363, 1311.
  • the X-ray powder diffraction pattern has characteristic peaks at reflection angles 2 ⁇ of about 4.88°, 9.68°, 12.74°, 14.52°, 17.72°, 19.82°, 21.86°, 24.30°, 25.26°; the infrared spectrum is shown in Fig. 6 a characteristic absorption peak at about 3423, 3352, 3238, 3030, 1624, 1597, 1531, 1502, 1452, 1423, 1388, 1365, 1308, 1255, 1226, 1159, 1086, 1022 cm -1 ;
  • the scanning calorimetry curve is shown in Figure 7. It has an endothermic peak at about 178.6 °C; its proton nuclear magnetic resonance spectrum indicates that the crystal does not contain organic solvents.
  • the X-ray powder diffraction pattern has an angle of reflection of 2 ⁇ of about 4.84°, 9.68°, 12.92°, 14.60°, 16.46°, 17.20°, 17.44°, 17.88°. Characteristic peaks at 19.20°, 20.54°, 21.06°, 22.00°, 25.28°, and 27.66°; the infrared spectrum is shown in FIG.
  • the unsolvated crystal A of Example 1, the unsolvated crystal B of Example 2, and the unsolvated crystal C of Example 3 were subjected to high temperature (60 ° C) and high humidity according to the Chinese Pharmacopoeia 2010 edition two appendix XIX C ( 90%) and strong light irradiation (4500Lx) test, the X-ray powder diffraction pattern and content (HPLC method) were sampled on the 0th day and the 10th day respectively. The test results showed that all the crystals retained the original crystal form. No change, the content of each crystal has not changed significantly, and all three crystals are suitable for pharmaceutical manufacturing and long-term storage.
  • Example 5 Preparation of Unsolvated Crystal A Tablets of Example 1
  • Example 1 unsolvated crystal A was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, sodium carboxymethyl starch and talc were passed through an 80 mesh sieve. The prescribed amount of microcrystalline cellulose, sodium carboxymethyl starch and unsolvated crystal A were weighed and mixed well. Add 4% povidone K30 ethanol solution to the appropriate amount, granulate and dry. Add the prescribed amount of talcum powder, mix and compress.
  • Example 6 Preparation of Capsules of Unsolvated Crystal A of Example 1
  • Preparation Process The unsolvated crystal A of Example 1 was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, lactose, sodium carboxymethyl starch, and magnesium stearate were passed through an 80 mesh sieve. Weigh the prescribed amount of microcrystalline cellulose, lactose, sodium carboxymethyl starch, unsolvated crystal A and magnesium stearate, mix well, and fill the capsule.
  • Example 7 Preparation of Unsolvated Crystal B Tablets of Example 2
  • Preparation Process The unsolvated crystal B of Example 2 was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, sodium carboxymethyl starch, and talc were passed through an 80 mesh sieve. The prescribed amount of microcrystalline cellulose, sodium carboxymethyl starch and unsolvated crystal B were weighed and mixed well. Add 4% povidone K30 ethanol solution to the appropriate amount, granulate and dry. Add the prescribed amount of talcum powder, mix and compress.
  • Preparation Process The unsolvated crystal B of Example 2 was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, lactose, sodium carboxymethyl starch, and magnesium stearate were passed through an 80 mesh sieve. Weigh the prescribed amount of microcrystalline cellulose, lactose, sodium carboxymethyl starch, unsolvated crystal B and magnesium stearate, mix well, and fill the capsule.
  • Example 9 Preparation of a tablet of unsolvated crystal C of Example 3
  • Preparation Process The unsolvated crystal C of Example 3 was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, sodium carboxymethyl starch, and talc were passed through an 80 mesh sieve. The prescribed amount of microcrystalline cellulose, sodium carboxymethyl starch and unsolvated crystal C were weighed and mixed well. Add 4% povidone K30 ethanol solution to the appropriate amount, granulate and dry. Add the prescribed amount of talcum powder, mix and compress.
  • Preparation Process The unsolvated crystal C of Example 3 was pulverized and passed through a 100 mesh sieve, and microcrystalline cellulose, lactose, sodium carboxymethyl starch, and magnesium stearate were passed through an 80 mesh sieve. Weigh the prescribed amount of microcrystalline cellulose, lactose, sodium carboxymethyl starch, unsolvated crystal C and magnesium stearate, mix well, and fill the capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘酰胺的非溶剂化晶体A、B、C及其制备方法。本发明还涉及含有所述晶体的药物组合物，以及所述晶体在制备用于治疗与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病的药物中的应用。

Description

一种非溶剂化晶体及其制备方法与应用
本申请要求于2016年09月27日提交中国专利局、申请号为201610856945.2、发明名称为“N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体及其制备方法与应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及药物化学领域，具体涉及N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体及其制备方法与应用。
背景技术
N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺是一种蛋白激酶和组蛋白去乙酰化酶双靶点抑制剂，其化学结构如结构式(I)所示。
Figure PCTCN2017103620-appb-000001
在中国专利申请CN200910223861.5中记载了式(I)化合物的药理活性，该化合物具有蛋白激酶抑制活性和组蛋白去乙酰化酶抑制活性，可以用于治疗与蛋白激酶活性异常以及组蛋白去乙酰化酶活性异常相关的疾病，包括炎症、自身免疫性疾病、癌症、神经系统疾病和神经退化性疾病、 心血管疾病、代谢病、过敏、哮喘以及与激素相关的疾病，尤其对血癌和实体瘤具有优异疗效。
本申请人按照中国专利申请CN200910223861.5实施例31所述方法制备了式(I)化合物，所得固体的X-射线粉末衍射图如图1所示。事实上，由该方法制备的式(I)化合物固体中不可避免地含有N,N-二甲基甲酰胺(DMF)，这已经由其质子核磁共振图谱(1H NMR)证实。所得固体为N,N-二甲基甲酰胺(DMF)的溶剂化晶体，含有1.4％的DMF。
由于有机溶剂对用药者具有潜在的毒性，因此，通常不宜制备含有机溶剂的晶体。人用药品注册技术要求国际协调会议(ICH，International Conference of Harmonizition)规定了多种常用有机溶剂在药品中的残留限度，例如N,N-二甲基甲酰胺(DMF)、氯仿、甲醇、四氢呋喃、甲苯、乙酸乙酯、乙酸丁酯、二甲亚砜(DMSO)、乙醇、甲基异丁基酮的限度分别为0.088％、0.006％、0.3％、0.072％、0.089％、0.5％、0.5％、0.5％、0.5％和0.5％。
按照中国专利申请CN200910223861.5实施例31的方法制得的式(I)化合物，其DMF的残留量远远超过了ICH规定的限度。针对式(I)化合物，本领域尚未有制备其非溶剂化晶体的方法。因此，迫切需要制备式(I)化合物的非溶剂化晶体，以使其安全地用于药物制造。
发明内容
本发明的目的在于克服现有技术的缺点，提供式(I)化合物的非溶剂化晶体。
本发明提供了3种式(I)化合物的非溶剂化晶体。
式(I)化合物的非溶剂化晶体A，其X-射线粉末衍射图在反射角2θ约4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、15.78°、18.58°、20.86°、 22.56°、25.72°、27.08°和28.72°处有特征峰；其红外光谱在约3452、3404、3357、3230、3064、1622、1576、1525、1506、1452、1423、1388、1363、1311、1253、1224、1161、1088和1024cm-1处有特征吸收峰；其差示扫描量热分析曲线在约177.5℃、213.1℃和220.8℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂，完全符合ICH对溶剂残留限度的规定。
式(I)化合物的非溶剂化晶体B，其X-射线粉末衍射图在反射角2θ约4.88°、9.68°、12.74°、14.52°、17.72°、19.82°、21.86°、24.30°、25.26°处具有特征峰；其红外光谱在约3423、3352、3238、3030、1624、1597、1531、1502、1452、1423、1388、1365、1308、1255、1226、1159、1086、1022cm-1处具有特征吸收峰；其差示扫描量热分析曲线在约178.6℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂，完全符合ICH对溶剂残留限度的规定。
式(I)化合物的非溶剂化晶体C，其X-射线粉末衍射图在反射角2θ约4.84°、9.68°、12.92°、14.60°、16.46°、17.20°、17.44°、17.88°、19.20°、20.54°、21.06°、22.00°、25.28°、27.66°处具有特征峰；其红外光谱在约3452、3369、3217、3016、2962、1793、1728、1626、1595、1574、1531、1502、1448、1429、1388、1311、1252、1224、1159、1020cm-1处具有特征吸收峰；其差示扫描量热分析曲线在约196.3℃和221.0℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂，完全符合ICH对溶剂残留限度的规定。
因此，在本发明的第一个方面，提供了N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体。
在一个实施方案中，所述非溶剂化晶体包括N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体A、B和C。
在一个实施方案中，所述非溶剂化晶体A的特征在于，其X-射线粉 末衍射图在反射角(2θ)6.88°、9.26°、12.74°、13.82°、18.58°、20.86°和25.72°处有特征峰；优选地，其X-射线粉末衍射图在反射角(2θ)4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、18.58°、20.86°和25.72°处有特征峰；更优选地，其X-射线粉末衍射图在反射角(2θ)4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、15.78°、18.58°、20.86°、22.56°、25.72°、27.08°和28.72°处有特征峰；最优选地，其X-射线粉末衍射图如图2所示。
在一个实施方案中，所述非溶剂化晶体A的红外光谱在3452、3404、3357、3230、3064、1622、1576、1525、1506、1452、1423、1388、1363、1311、1253、1224、1161、1088和1024cm-1处有特征吸收峰，优选地如图3所示；其差示扫描量热分析曲线在177.5℃、213.1℃和220.8℃有吸热峰，优选地如图4所示。
在一个实施方案中，所述非溶剂化晶体B的特征在于，其X-射线粉末衍射图在反射角(2θ)4.88°、9.68°、12.74°、14.52°、17.72°、24.30°、25.26°处具有特征峰；优选地，其X-射线粉末衍射图在反射角(2θ)4.88°、9.68°、12.74°、14.52°、17.72°、19.82°、21.86°、24.30°、25.26°处具有特征峰；更优选地，其X-射线粉末衍射图如图5所示。
在一个实施方案中，所述非溶剂化晶体B的红外光谱在3423、3352、3238、3030、1624、1597、1531、1502、1452、1423、1388、1365、1308、1255、1226、1159、1086、1022cm-1处具有特征吸收峰，优选地如图6所示；其差示扫描量热分析曲线在178.6℃有吸热峰，优选地如图7所示。
在一个实施方案中，所述非溶剂化晶体C的特征在于，其X-射线粉末衍射图在反射角(2θ)4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、22.00°、25.28°处具有特征峰；优选地，其X-射线粉末衍射图在反射角(2θ)4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、17.88°、22.00°、25.28°、27.66°处具有特征峰；更优选地，其X-射线粉末衍射图在反射角(2θ)4.84 °、9.68°、12.92°、14.60°、16.46°、17.20°、17.44°、17.88°、19.20°、20.54°、21.06°、22.00°、25.28°、27.66°处具有特征峰；最优选地，其X-射线粉末衍射图如图8所示。
在一个实施方案中，所述非溶剂化晶体C的红外光谱在3452、3369、3217、3016、2962、1793、1728、1626、1595、1574、1531、1502、1448、1429、1388、1311、1252、1224、1159、1020cm-1处具有特征吸收峰，优选地如图9所示；其差示扫描量热分析曲线在196.3℃和221.0℃有吸热峰，优选地如图10所示。
本发明还提供了3种式(I)化合物的非溶剂化晶体的制备方法。
式(I)化合物的非溶剂化晶体A的制备方法：该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入甲醇中，于65℃加热溶解，于0℃冷却析出。在一个优选的实施方案中，非溶剂化晶体A的制备方法包括以下步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入甲醇中，于65℃加热溶解，于0℃冷却析出，过滤收集固体，于80℃真空干燥12小时即得。
式(I)化合物的非溶剂化晶体B的制备方法，该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入乙腈中，于80℃加热溶解，于0℃冷却析出。在一个优选的实施方案中，非溶剂化晶体B的制备方法包括以下步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入乙腈中，于80℃加热溶解，于0℃冷却析出，过滤收集，于80℃真空干燥12小时即得。
式(I)化合物的非溶剂化晶体C的制备方法，该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入二甲亚砜中，于室温下搅拌溶解，将所得溶液于搅拌下滴入水中，过滤收集固体。在一个优选的实施方案中，非溶剂化晶体C的制备方法包括以下步骤：将N-(2-氨基 苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入二甲亚砜中，于室温下搅拌溶解，将所得溶液于搅拌下滴入水中，过滤收集固体，水洗，于80℃真空干燥24小时即得。
在本发明的另一方面，提供了一种药物组合物，其包含N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体。在一个实施方案中，本发明提供了一种用于治疗与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病的药物组合物，其包含N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体，以及任选地可药用赋形剂和/或载体。
本发明的药物组合物可以含有任何合适的可药用赋形剂和/或载体。本发明的药物组合物可以通过常规技术制备，例如在Remington：The Science and Practice of Pharmacy,第19版，1995中所描述的方法，其通过引用并入本文。所述组合物可以以常规形式出现，例如片剂、胶囊、粉剂、颗粒剂、悬浮剂、糖浆、液剂、针剂、膏剂等。该制剂中通常含有0.5％～70％wt的式(I)化合物以及30％～99.5％wt的药用辅料，优选含有1％～65％wt、3％～60％wt、5％～55％wt、10％～50％wt、20％～40％wt、25％～38％wt、30％～35％wt或32％～34％wt的式(I)化合物。
典型的组合物包含本发明化合物和赋形剂或载体。例如，活性化合物通常与载体混合，或者被载体稀释，或者被密封在可以为安瓿、胶囊、小药囊(sachet)、纸或其它容器形式的载体内。当将活性化合物与载体混合时，或者当载体充当稀释剂时，所述载体可以为充当活性化合物的载体、赋形剂或介质的固体、半固体或液体材料。所述活性化合物可以吸附在颗粒状固体载体上(例如容纳在小药囊中)。合适的载体的一些实例为水、盐溶液、醇、聚乙二醇、聚羟基乙氧基化蓖麻油、花生油、橄榄油、明胶、乳糖、白土、蔗糖、糊精、碳酸镁、糖、环糊精、直链淀粉、硬脂酸镁、滑石、明胶、琼脂、果胶、阿拉伯胶、硬脂酸或纤维素的低级烷基醚、硅 酸、脂肪酸、脂肪酸胺、脂肪酸甘油单酯和甘油二酯、季戊四醇脂肪酸酯、聚氧乙烯、羟甲基纤维素和聚乙烯吡咯烷酮。类似地，所述载体或稀释剂可以包括任何本领域已知的持续释放材料，例如单独的单硬脂酸甘油酯或二硬脂酸甘油酯或者其与蜡的混合物。
在本发明的又一个方面，本发明提供了N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体在制备用于治疗与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病的药物中的应用。优选地，所述与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病选自炎症、自身免疫性疾病、癌症、神经系统疾病和神经退化性疾病、心血管疾病、代谢病、过敏、哮喘以及与激素相关的疾病，尤其是血癌和实体瘤。
将式(I)化合物的非溶剂化晶体A、B和C在高温(60℃)、高湿(90％士5％)和强光照射(4500Lx士500Lx)下放置10天，三种晶体均保持原有晶型不变，各晶体的含量亦未发生明显改变，这表明三种晶体均适合药剂制造和长期储存。
附图说明
图1是根据中国专利申请CN200910223861.5所述的实施例31制得的固体的X-射线粉末衍射图。
图2是根据本发明实施例1制备的式(I)化合物的非溶剂化晶体A的X-射线粉末衍射图。
图3是根据本发明实施例1制备的式(I)化合物的非溶剂化晶体A的红外光谱图。
图4是根据本发明实施例1制备的式(I)化合物的非溶剂化晶体A的差示扫描量热分析曲线图。
图5是根据本发明实施例2制备的式(I)化合物的非溶剂化晶体B 的X-射线粉末衍射图。
图6是根据本发明实施例2制备的式(I)化合物的非溶剂化晶体B的红外光谱图。
图7是根据本发明实施例2制备的式(I)化合物的非溶剂化晶体B的差示扫描量热分析曲线图。
图8是根据本发明实施例3制备的式(I)化合物的非溶剂化晶体C的X-射线粉末衍射图。
图9是根据本发明实施例3制备的式(I)化合物的非溶剂化晶体C的红外光谱图。
图10是根据本发明实施例3制备的式(I)化合物的非溶剂化晶体C的差示扫描量热分析曲线图。
具体实施方式
下面结合实例进一步阐明本发明的内容，但本发明的保护范围并不仅仅局限于这些实例。本发明所述的百分比除特别注明外，均为重量百分比。说明书中所描述的数值范围，如计量单位、反应条件、化合物物理状态或百分比，均是为了提供明白无误的书面参考。本领域熟练技术人员在实践本专利时，使用在此范围之外或有别于单个数值的温度、浓度、数量、碳原子数等，仍然可以得到预期的结果。
试验方法：
X-射线粉末衍射测试条件：仪器：D/MAX-1200(日本Rigaku公司)；辐射源：Cu-Kα(40kV、40mA)。
红外光谱测试条件：仪器：RFX-65A(美国Analect公司)；KBr压片法。
差示扫描量热分析测试条件：仪器：Pyris-1-DSC(美国PerkinElmer 公司)；升温速率：10℃/min；氮气流速：40mL/min。
质子核磁共振测试条件：仪器：AV-400(德国BRUKER公司)；溶剂：DMSO-d6。
稳定性试验条件：按中国药典2010年版二部附录XIX C进行高温(60℃)、高湿(90％)和强光照射(4500Lx)试验。
HPLC测试条件：仪器：戴安UltiMate3000；色谱柱：Shim-pack VP-ODS 5μm 250L×4.6；检测器：VWD-3100，检测波长：256nm；流动相:甲醇-水-冰醋酸(30:70:0.4)；流速；1.0mL/min，柱温：30℃。
实施例1：N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体A的制备
将5.0g N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺置于2000mL三口烧瓶中，加入750mL甲醇，于65℃油浴加热搅拌至溶解。将所得溶液置于0℃冰水浴中冷却析晶4小时，过滤收集固体，于80℃真空干燥12小时，得到非溶剂化晶体A。其X-射线粉末衍射图如图2所示，在反射角2θ约4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、15.78°、18.58°、20.86°、22.56°、25.72°、27.08°和28.72°处有特征峰；其红外光谱如图3所示，在约3452、3404、3357、3230、3064、1622、1576、1525、1506、1452、1423、1388、1363、1311、1253、1224、1161、1088和1024cm-1处有特征吸收峰；其差示扫描量热分析曲线如图4所示，在约177.5℃、213.1℃和220.8℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂。
实施例2：N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体B的制备
将5.0g N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺置于2000mL三口烧瓶中，加入1000mL乙腈，于80℃油浴加热搅拌至溶解。将所得溶液置于0℃冰水浴中冷却析晶4小时，过滤收集固体，于80℃真空干燥12小时，得到非溶剂化晶体B。该晶体的X-射线粉末衍射图如图5所示。其X-射线粉末衍射图在反射角2θ约4.88°、9.68°、12.74°、14.52°、17.72°、19.82°、21.86°、24.30°、25.26°处具有特征峰；其红外光谱如图6所示，在约3423、3352、3238、3030、1624、1597、1531、1502、1452、1423、1388、1365、1308、1255、1226、1159、1086、1022cm-1处具有特征吸收峰；其差示扫描量热分析曲线如图7所示，在约178.6℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂。
实施例3：N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体C的制备
将1.0g N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺置于50mL三口烧瓶中，加入5mL二甲亚砜，室温搅拌至溶解。将所得溶液于搅拌下滴入50mL水中，静止4小时，过滤，水洗，收集固体，于80℃真空干燥24小时，得到非溶剂化晶体C。该晶体的X-射线粉末衍射图如图8所示，其X-射线粉末衍射图在反射角2θ约4.84°、9.68°、12.92°、14.60°、16.46°、17.20°、17.44°、17.88°、19.20°、20.54°、21.06°、22.00°、25.28°、27.66°处具有特征峰；其红外光谱如图9所示，在约3452、3369、3217、3016、2962、1793、1728、1626、1595、1574、1531、1502、1448、1429、1388、1311、1252、1224、1159、1020cm-1处具有特征吸收峰；其差示扫描量热分析曲线如图10所示，在约196.3℃和221.0℃有吸热峰；其质子核磁共振图谱表明该晶体不含有机溶剂。
实施例4：晶型稳定性试验
将实施例1的非溶剂化晶体A、实施例2的非溶剂化晶体B和实施例3的非溶剂化晶体C按中国药典2010年版二部附录XIX C进行高温(60℃)、高湿(90％)和强光照射(4500Lx)试验，分别在第0天和第10天取样测定其X-射线粉末衍射图和含量(HPLC法)，试验结果表明，三种晶体均保持原有晶型不变，各晶体的含量亦未发生明显改变，三种晶体均适合药剂制造和长期储存。
实施例5：实施例1的非溶剂化晶体A的片剂的制备
处方(1000片)：
Figure PCTCN2017103620-appb-000002
制备工艺：将实施例1非溶剂化晶体A粉碎并过100目筛，将微晶纤维素、羧甲基淀粉钠和滑石粉过80目筛。称取处方量的微晶纤维素、羧甲基淀粉钠和非溶剂化晶体A，混合均匀。加入4％的聚维酮K30乙醇溶液适量，制粒，干燥。加入处方量滑石粉，混匀，压片即得。
实施例6：实施例1的非溶剂化晶体A的胶囊的制备
处方(1000粒)：
Figure PCTCN2017103620-appb-000003
制备工艺：将实施例1的非溶剂化晶体A粉碎并过100目筛，将微晶纤维素、乳糖、羧甲基淀粉钠和硬脂酸镁过80目筛。称取处方量的微晶纤维素、乳糖、羧甲基淀粉钠、非溶剂化晶体A和硬脂酸镁，混合均匀，灌装胶囊即得。
实施例7：实施例2的非溶剂化晶体B的片剂的制备
处方(1000片)：
Figure PCTCN2017103620-appb-000004
Figure PCTCN2017103620-appb-000005
制备工艺：将实施例2的非溶剂化晶体B粉碎并过100目筛，将微晶纤维素、羧甲基淀粉钠和滑石粉过80目筛。称取处方量的微晶纤维素、羧甲基淀粉钠和非溶剂化晶体B，混合均匀。加入4％的聚维酮K30乙醇溶液适量，制粒，干燥。加入处方量滑石粉，混匀，压片即得。
实施例8：实施例2的非溶剂化晶体B的胶囊的制备
处方(1000粒)：
Figure PCTCN2017103620-appb-000006
制备工艺：将实施例2的非溶剂化晶体B粉碎并过100目筛，将微晶纤维素、乳糖、羧甲基淀粉钠和硬脂酸镁过80目筛。称取处方量的微晶纤维素、乳糖、羧甲基淀粉钠、非溶剂化晶体B和硬脂酸镁，混合均匀，灌装胶囊即得。
实施例9：实施例3的非溶剂化晶体C的片剂的制备
处方(1000片)：
Figure PCTCN2017103620-appb-000007
制备工艺：将实施例3的非溶剂化晶体C粉碎并过100目筛，将微晶纤维素、羧甲基淀粉钠和滑石粉过80目筛。称取处方量的微晶纤维素、羧甲基淀粉钠和非溶剂化晶体C，混合均匀。加入4％的聚维酮K30乙醇溶液适量，制粒，干燥。加入处方量滑石粉，混匀，压片即得。
实施例10：实施例3的非溶剂化晶体C的胶囊的制备
处方(1000粒)：
Figure PCTCN2017103620-appb-000008
制备工艺：将实施例3的非溶剂化晶体C粉碎并过100目筛，将微晶纤维素、乳糖、羧甲基淀粉钠和硬脂酸镁过80目筛。称取处方量的微晶纤维素、乳糖、羧甲基淀粉钠、非溶剂化晶体C和硬脂酸镁，混合均匀，灌装胶囊即得。

Claims (13)

  1. N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体。
  2. 如权利要求1所述的非溶剂化晶体，其中所述非溶剂化晶体为N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体A，其X-射线粉末衍射图在反射角2θ为6.88°、9.26°、12.74°、13.82°、18.58°、20.86°和25.72°处有特征峰；优选地，其X-射线粉末衍射图在反射角2θ为4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、18.58°、20.86°和25.72°处有特征峰；更优选地，其X-射线粉末衍射图在反射角2θ为4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、15.78°、18.58°、20.86°、22.56°、25.72°、27.08°和28.72°处有特征峰；最优选地，其X-射线粉末衍射图如图2所示。
  3. 如权利要求2所述的非溶剂化晶体，其中所述非溶剂化晶体A的红外光谱在3452、3404、3357、3230、3064、1622、1576、1525、1506、1452、1423、1388、1363、1311、1253、1224、1161、1088和1024cm-1处有特征吸收峰；和/或其差示扫描量热分析曲线在177.5℃、213.1℃和220.8℃有吸热峰。
  4. 如权利要求1所述的非溶剂化晶体，其中所述非溶剂化晶体为N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体B，其X-射线粉末衍射图在反射角2θ为4.88°、9.68°、12.74°、14.52°、17.72°、24.30°、25.26°处具有特征峰；优选地，其X-射线粉末衍射图在反射角2θ为4.88°、9.68°、12.74°、14.52°、17.72°、19.82°、21.86°、24.30°、25.26°处具有特征峰；更优选地，其X-射线粉末衍射图如图5所示。
  5. 如权利要求4所述的非溶剂化晶体，其中所述非溶剂化晶体B的红外光谱在3423、3352、3238、3030、1624、1597、1531、1502、1452、1423、1388、1365、1308、1255、1226、1159、1086、1022cm-1处具有特征吸收峰；和/或其差示扫描量热分析曲线在178.6℃有吸热峰。
  6. 如权利要求1所述的非溶剂化晶体，其中所述非溶剂化晶体为N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体C，其X-射线粉末衍射图在反射角2θ为4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、22.00°、25.28°处具有特征峰；优选地，其X-射线粉末衍射图在反射角2θ 为4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、17.88°、22.00°、25.28°、27.66°处具有特征峰；更优选地，其X-射线粉末衍射图在反射角2θ为4.84°、9.68°、12.92°、14.60°、16.46°、17.20°、17.44°、17.88°、19.20°、20.54°、21.06°、22.00°、25.28°、27.66°处具有特征峰；最优选地，其X-射线粉末衍射图如图8所示。
  7. 如权利要求6所述的非溶剂化晶体，其中所述非溶剂化晶体C的红外光谱在3452、3369、3217、3016、2962、1793、1728、1626、1595、1574、1531、1502、1448、1429、1388、1311、1252、1224、1159、1020cm-1处具有特征吸收峰；和/或其差示扫描量热分析曲线在196.3℃和221.0℃有吸热峰。
  8. 制备如权利要求2至3中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体A的方法，该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入甲醇中，于65℃加热溶解，于0℃冷却析出。
  9. 制备如权利要求4至5中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体B的方法，该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入乙腈中，于80℃加热溶解，于0℃冷却析出。
  10. 制备如权利要求6至7中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体C的方法，该方法包括下列步骤：将N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺加入二甲亚砜中，于室温下搅拌溶解，将所得溶液于搅拌下滴入水中，过滤收集固体。
  11. 一种药物组合物，其包含如权利要求1至7中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体。
  12. 一种用于治疗与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病的药物组合物，其包含如权利要求1至7中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体。
  13. 如权利要求1至7中任一项所述的N-(2-氨基苯基)-6-(7-甲氧基喹啉-4-氧)-1-萘甲酰胺的非溶剂化晶体在制备用于治疗与蛋白激酶活性异常或组蛋白去乙酰化酶活性异常相关的疾病的药物中的应用。
PCT/CN2017/103620 2016-09-27 2017-09-27 一种非溶剂化晶体及其制备方法与应用 WO2018059429A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2017333056A AU2017333056B2 (en) 2016-09-27 2017-09-27 Non-solvated crystal, preparation method and application thereof
RU2019112457A RU2019112457A (ru) 2016-09-27 2017-09-27 Несольватированный кристалл, способ его получения и его применение
CA3038384A CA3038384C (en) 2016-09-27 2017-09-27 Non-solvated crystal of n-(2-aminophenyl)-6-(7-methoxyquinoline-4-oxo)-1-naphthaleneformamide, preparation method and application thereof
BR112019005995A BR112019005995A2 (pt) 2016-09-27 2017-09-27 cristal não solvatado, método de preparação e aplicação do mesmo
EP17854879.8A EP3524594A4 (en) 2016-09-27 2017-09-27 NON-SOLVATED CRYSTAL, PRODUCTION METHOD AND APPLICATION THEREOF
UAA201904447A UA123746C2 (uk) 2016-09-27 2017-09-27 Несольватований кристал, спосіб його одержання і його застосування
MX2019003458A MX2019003458A (es) 2016-09-27 2017-09-27 Cristal no solvatado, metodo de preparacion y aplicacion del mismo.
KR1020197012102A KR20190053952A (ko) 2016-09-27 2017-09-27 비용매화된 결정, 이의 제조방법 및 용도
US16/337,389 US10882825B2 (en) 2016-09-27 2017-09-27 Non-solvated crystal, preparation method and application thereof
JP2019517848A JP7339884B2 (ja) 2016-09-27 2017-09-27 非溶媒和物結晶及びその製造方法、並びに応用
ZA2019/02628A ZA201902628B (en) 2016-09-27 2019-04-25 Non-solvated crystal, preparation method and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610856945.2A CN107868044B (zh) 2016-09-27 2016-09-27 一种非溶剂化晶体及其制备方法与应用
CN201610856945.2 2016-09-27

Publications (1)

Publication Number Publication Date
WO2018059429A1 true WO2018059429A1 (zh) 2018-04-05

Family

ID=61751435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/103620 WO2018059429A1 (zh) 2016-09-27 2017-09-27 一种非溶剂化晶体及其制备方法与应用

Country Status (14)

Country Link
US (1) US10882825B2 (zh)
EP (1) EP3524594A4 (zh)
JP (2) JP7339884B2 (zh)
KR (1) KR20190053952A (zh)
CN (1) CN107868044B (zh)
AU (1) AU2017333056B2 (zh)
BR (1) BR112019005995A2 (zh)
CA (1) CA3038384C (zh)
MX (1) MX2019003458A (zh)
RU (1) RU2019112457A (zh)
TW (1) TWI724242B (zh)
UA (1) UA123746C2 (zh)
WO (1) WO2018059429A1 (zh)
ZA (1) ZA201902628B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527202A (zh) * 2020-04-21 2021-10-22 健亚生物科技股份有限公司 一种硫酸羟氯喹晶体
WO2022052874A1 (zh) * 2020-09-09 2022-03-17 深圳微芯生物科技股份有限公司 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
RU2784869C1 (ru) * 2019-03-25 2022-11-30 Шэньчжэнь Чипскрин Байосайенсиз Ко., Лтд. Чиаураниб для лечения мелкоклеточного рака легкого

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107868044B (zh) * 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用
CN109908143B (zh) * 2018-12-18 2021-11-19 厦门大学附属第一医院 西奥罗尼在制备治疗急性髓系白血病药物的新用途
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298358A1 (en) * 2009-05-22 2010-11-25 Shenzhen Chipscreen Biosciences Ltd. Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
CN101906076A (zh) * 2009-06-04 2010-12-08 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833626B (zh) * 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
CN103288728A (zh) * 2013-05-17 2013-09-11 华侨大学 一种萘甲酰胺衍生物、其制备方法以及应用
CN103896836A (zh) * 2014-03-20 2014-07-02 华侨大学 N-苯基-6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺及其制备方法
CN103923004A (zh) * 2014-04-04 2014-07-16 华侨大学 一种萘甲酰胺衍生物及其制备和应用
CN107868044B (zh) * 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298358A1 (en) * 2009-05-22 2010-11-25 Shenzhen Chipscreen Biosciences Ltd. Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors
CN101906076A (zh) * 2009-06-04 2010-12-08 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 1995

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2784869C1 (ru) * 2019-03-25 2022-11-30 Шэньчжэнь Чипскрин Байосайенсиз Ко., Лтд. Чиаураниб для лечения мелкоклеточного рака легкого
CN113527202A (zh) * 2020-04-21 2021-10-22 健亚生物科技股份有限公司 一种硫酸羟氯喹晶体
WO2022052874A1 (zh) * 2020-09-09 2022-03-17 深圳微芯生物科技股份有限公司 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用

Also Published As

Publication number Publication date
ZA201902628B (en) 2021-09-29
KR20190053952A (ko) 2019-05-20
US20200031774A1 (en) 2020-01-30
BR112019005995A2 (pt) 2019-07-09
JP7339884B2 (ja) 2023-09-06
CA3038384A1 (en) 2018-04-05
CN107868044B (zh) 2020-10-16
JP2019529504A (ja) 2019-10-17
JP2021105043A (ja) 2021-07-26
RU2019112457A3 (zh) 2020-11-02
US10882825B2 (en) 2021-01-05
CN107868044A (zh) 2018-04-03
MX2019003458A (es) 2019-10-15
AU2017333056B2 (en) 2020-07-02
EP3524594A1 (en) 2019-08-14
AU2017333056A1 (en) 2019-05-02
EP3524594A4 (en) 2020-03-04
RU2019112457A (ru) 2020-11-02
TW201813957A (zh) 2018-04-16
CA3038384C (en) 2021-11-02
TWI724242B (zh) 2021-04-11
UA123746C2 (uk) 2021-05-26

Similar Documents

Publication Publication Date Title
WO2018059429A1 (zh) 一种非溶剂化晶体及其制备方法与应用
CA2891006C (en) Crystal form of chidamide, preparation method and use thereof
WO2016124067A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
WO2021129589A1 (zh) Kd-025的新晶型及其制备方法
BR112019021447A2 (pt) sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica
WO2016070697A1 (zh) 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
US9255063B2 (en) Colchicine solid-state forms; methods of making; and methods of use thereof
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2018133823A1 (zh) 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN109280032B (zh) 一种哒嗪酮母核结构的组蛋白去乙酰化酶抑制剂及其制备方法和用途
WO2017041622A1 (zh) 一种雄性激素受体抑制剂的结晶形式及其制备方法
WO2016050134A1 (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
CN117545755A (zh) 一种Lanifibranor的晶型及其制备方法
WO2018001335A1 (zh) Nbi-98854的晶型及其制备方法和用途
WO2022194160A1 (zh) 非索替尼固体形式及其制备方法
WO2019242717A1 (zh) 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
WO2015062481A1 (zh) 替莫唑胺晶型及其制备方法
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JP2023532217A (ja) Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用
WO2017107945A1 (zh) 二肽基肽酶-iv抑制剂的苯甲酸盐的晶型

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17854879

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3038384

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019517848

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019005995

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197012102

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017333056

Country of ref document: AU

Date of ref document: 20170927

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017854879

Country of ref document: EP

Effective date: 20190429

ENP Entry into the national phase

Ref document number: 112019005995

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190326